WhitTier Trust Company’s Corvus Pharmaceuticals CRVS Stock Holding History

WhitTier Trust Company’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$159K	Hold	10,200	–	–	﹤0.01%	542
2026 Q1	$150K	Sell	10,200 -1,000	-9%	-$16K	﹤0.01%	534
2025 Q4	$74.8K	Hold	11,200	–	–	﹤0.01%	637
2025 Q3	$80.5K	Hold	11,200	–	–	﹤0.01%	599
2025 Q2	$44.8K	Hold	11,200	–	–	﹤0.01%	812
2025 Q1	$35.6K	Hold	11,200	–	–	﹤0.01%	846
2024 Q4	$59.9K	Hold	11,200	–	–	﹤0.01%	708
2024 Q3	$59K	Hold	11,200	–	–	﹤0.01%	713
2024 Q2	$20.3K	Hold	11,200	–	–	﹤0.01%	886
2024 Q1	$19.8K	Hold	11,200	–	–	﹤0.01%	856
2023 Q4	$19.6K	Hold	11,200	–	–	﹤0.01%	845
2023 Q3	$16.4K	Buy	11,200 +7,000	+167%	+$14.8K	﹤0.01%	846
2023 Q2	$9.58K	Hold	4,200	–	–	﹤0.01%	960
2023 Q1	$3.82K	Hold	4,200	–	–	﹤0.01%	1039
2022 Q4	$3.57K	Hold	4,200	–	–	﹤0.01%	1044
2022 Q3	$3K	Hold	4,200	–	–	﹤0.01%	1006
2022 Q2	$4K	Hold	4,200	–	–	﹤0.01%	1012
2022 Q1	$7K	Hold	4,200	–	–	﹤0.01%	974
2021 Q4	$10K	Hold	4,200	–	–	﹤0.01%	903
2021 Q3	$20K	Hold	4,200	–	–	﹤0.01%	829
2021 Q2	$11K	Hold	4,200	–	–	﹤0.01%	857
2021 Q1	$13K	Hold	4,200	–	–	﹤0.01%	825
2020 Q4	$15K	Hold	4,200	–	–	﹤0.01%	788
2020 Q3	$17K	Buy	+4,200	New	+$16.8K	﹤0.01%	756

Other funds holding CRVS

Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return

SAM

SEB Asset Management Stockholm $26.6B AUM

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

FMI

F/M Investments Washington, District of Columbia $1.97B AUM 30.33% 1-Year Est. Return

Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

PAP

Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return

WhitTier Trust Company's CRVS Position: Q2 2026 in Review

WhitTier Trust Company held its Corvus Pharmaceuticals (CRVS) position steady in Q2 2026 at 10,200 shares worth $159K. The position accounts for ﹤0.01% of the portfolio, ranked #542.

WhitTier Trust Company first reported a position in CRVS in Q3 2020 and has held it in 24 quarters since. 47 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

WhitTier Trust Company held 10,200 shares of Corvus Pharmaceuticals worth $159K as of Q2 2026.
WhitTier Trust Company left its Corvus Pharmaceuticals share count unchanged in Q2 2026.
Corvus Pharmaceuticals made up ﹤0.01% of WhitTier Trust Company's portfolio in Q2 2026, its #542 holding.
WhitTier Trust Company first reported a position in Corvus Pharmaceuticals in Q3 2020 and has held it in 24 quarters since.
47 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on WhitTier Trust Company's 13F filing for Q2 2026, filed 28 Jul 2026.